Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Phases › Phase 2

Phase 2 (140 companies)

Companies with at least one active program at Phase 2.

Ticker Company Therapeutic areas Phase 2 programs Lead stage Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 2 Phase 3 5
ACIU AC Immune Neurology Rare 3 Phase 3 10
ACHV Achieve Life Sciences — 1 NDA Submitted 2
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 4 Phase 2 8
ACRV Acrivon Therapeutics Oncology 4 Phase 2 6
ACTU Actuate Therapeutics Oncology 1 Phase 2 4
ABOS Acumen Pharmaceuticals Neurology 1 Phase 2 4
ADAG Adagene Oncology 3 Phase 2 10
ADCT ADC Therapeutics Oncology 3 Approved 5
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 4 Approved 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 Rare 1 NDA Submitted 7
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 10
DRTS Alpha Tau Medical Oncology 4 Phase 2 6
ATHE Alterity Therapeutics Neurology Rare 1 Phase 2 2
ALT Altimmune GI/HepatologyMetabolic+1 2 Phase 3 3
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 5
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 1 Approved 6
ANNX Annexon HematologyNeurology+2 Rare 2 Phase 3 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 9
ARTV Artiva Biotherapeutics DermatologyImmunology+2 Rare 4 Phase 2 14
ARVN Arvinas NeurologyOncology Rare 1 Approved 12
ATAI Atai Beckley Neurology 3 Phase 2 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 2 Approved 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 6
BCAX Bicara Therapeutics Oncology 1 Phase 2 4
BIOA BioAge Labs CardiovascularOphthalmology 2 Phase 2 2
BMEA Biomea Fusion MetabolicOncology 1 Phase 2 4
CCCC C4 Therapeutics Oncology 1 Phase 2 2
CRDL Cardiol Therapeutics Cardiovascular Rare 1 Phase 3 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 4
CLDX Celldex Therapeutics DermatologyImmunology+1 1 Phase 3 7
CLRB Cellectar Biosciences Oncology 3 Phase 2 6
CRVO CervoMed Neurology Rare 3 Phase 2 4
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 2 Phase 2 4
CLNN Clene Neurology Rare 2 Phase 3 5
CLYM Climb Bio HematologyImmunology+1 Rare 2 Phase 2 7
CGTX Cognition Therapeutics Neurology 2 Phase 2 2
CMPS COMPASS Pathways Neurology 2 NDA Submitted 3
CMPX Compass Therapeutics Oncology 2 Phase 2 15
CGEN Compugen Oncology 1 Phase 3 7
CNTB Connect Biopharma Respiratory 4 Phase 2 4
CRVS Corvus Pharmaceuticals DermatologyOncology 2 Phase 3 4
CBIO Crescent Biopharma Oncology 1 Phase 2 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 1 Approved 6
CUE Cue Biopharma ImmunologyOncology 1 Phase 2 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted 10
HELP Cybin Neurology 2 Phase 3 3
CYDY CytoDyn NeurologyOncology 2 Phase 2 3
DFTX Definium Therapeutics Neurology 1 Phase 3 4
EIKN Eikon Therapeutics Oncology 2 Phase 2 13
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 2 Phase 2 3
ELTX Elicio Therapeutics Oncology 1 Phase 2 6
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 1 Phase 2 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 3 Phase 2 6
ENTX Entera Bio GI/HepatologyMetabolic Rare 1 Phase 2 4
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+2 Rare 1 Approved 14
EVMN Evommune DermatologyImmunology+1 5 Phase 2 5
EXEL Exelixis CardiovascularOncology 4 Approved 22
FBRX Forte Biosciences DermatologyGI/Hepatology 1 Phase 2 3
FBIO Fortress Biotech DermatologyHematology+2 Rare 1 Approved 12
GNLX Genelux Oncology 1 Phase 3 3
GERN Geron Oncology 1 Approved 3
GHRS GH Research NeurologyWomen's Health 3 Phase 2 4
GOSS Gossamer Bio Cardiovascular Rare 2 Phase 3 4
HRMY Harmony Biosciences MetabolicNeurology Rare 1 Approved 17
IMTX Immatics Oncology 1 Phase 3 8
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 4
IBRX ImmunityBio Infectious DiseaseOncology 6 Approved 16
IMVT Immunovant ImmunologyNeurology Rare 5 Phase 3 6
INAB IN8bio ImmunologyOncology 1 Phase 2 6
IXHL Incannex Healthcare ImmunologyNeurology+1 3 Phase 2 3
INBX Inhibrx Biosciences Oncology 1 NDA Submitted 6
INMB Inmune Bio DermatologyOncology Rare 1 Phase 2 2
INSM Insmed CardiovascularImmunology+2 Rare 2 Approved 17
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 4
KAPA Kairos Pharma Oncology 1 Phase 2 13
KZIA Kazia Therapeutics Oncology Rare 2 Phase 2 10
KPRX Kiora Pharmaceuticals Ophthalmology Rare 3 Phase 2 4
KYMR Kymera Therapeutics DermatologyRespiratory Rare 2 Phase 2 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 2 NDA Submitted 7
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 12
LGVN Longeveron CardiovascularMetabolic+1 Rare 2 Phase 2 4
MPLT MapLight Therapeutics Neurology 3 Phase 2 6
MDNAF Medicenna Therapeutics Oncology 1 Phase 2 9
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 1 Phase 2 16
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 2 Phase 2 7
MBRX Moleculin Biotech Oncology 2 Phase 2 10
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 2 Phase 2 7
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare 2 Phase 3 4
NKTR Nektar Therapeutics DermatologyImmunology+2 5 Phase 3 11
NRSN NeuroSense Therapeutics Neurology Rare 2 Phase 2 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 1 NDA Submitted 6
NBP NovaBridge Biosciences OncologyOphthalmology 3 Phase 2 6
NRIX Nurix Therapeutics ImmunologyNeurology+1 3 Phase 3 16
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 8
OCGN Ocugen Infectious DiseaseOphthalmology Rare 1 Phase 3 12
OCS Oculis Holding NeurologyOphthalmology Rare 1 Phase 3 4
OMER Omeros HematologyNeurology+2 Rare 1 Approved 6
ONCY Oncolytics Biotech Oncology 2 Phase 2 3
IRD Opus Genetics Ophthalmology Rare 1 Approved 12
ORKA Oruka Therapeutics DermatologyImmunology Rare 3 Phase 2 7
OVID Ovid Therapeutics Neurology Rare 1 Phase 2 4
PTN Palatin Technologies ImmunologyMetabolic+1 Rare 2 Phase 3 8
PEPG PepGen Neurology Rare 1 Phase 2 1
PMVP PMV Pharmaceuticals Oncology 7 Phase 2 7
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 7
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 3 Phase 3 3
QTTB Q32 Bio Dermatology 1 Phase 2 2
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 2 Phase 2 4
RNTX Rein Therapeutics Respiratory Rare 1 Phase 2 1
RLAY Relay Therapeutics DermatologyOncology Rare 2 NDA Submitted 5
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 3 Phase 2 4
REPL Replimune Group Oncology 4 Approved 5
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved 13
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 1 Approved 4
SABS SAB Biotherapeutics Metabolic 1 Phase 2 1
SGMT Sagimet Biosciences DermatologyMetabolic 1 NDA Submitted 3
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 9
SION Sionna Therapeutics Respiratory Rare 1 Phase 2 5
SYRE Spyre Therapeutics DermatologyImmunology Rare 11 Phase 2 12
SMMT Summit Therapeutics Oncology 1 NDA Submitted 5
SNDX Syndax Pharmaceuticals ImmunologyOncology+1 Rare 1 Approved 8
TECX Tectonic Therapeutic Cardiovascular Rare 2 Phase 2 3
TGTX Tg Therapeutics Neurology Rare 2 Approved 6
TVTX Travere Therapeutics MetabolicRenal Rare 1 Approved 7
TTRX Turn Therapeutics DermatologyInfectious Disease Rare 1 Phase 2 4
TYRA Tyra Biosciences MetabolicOncology Rare 3 Phase 2 5
RARE Ultragenyx Pharmaceutical CardiovascularGI/Hepatology+2 Rare 1 Approved 12
PCVX Vaxcyte Infectious Disease 1 Phase 3 6
VERA Vera Therapeutics Infectious DiseaseRenal Rare 4 Approved 6
VSTM Verastem Oncology 4 Approved 5
VRCA Verrica Pharmaceuticals DermatologyOncology 1 Approved 3
VKTX Viking Therapeutics MetabolicNeurology Rare 4 Phase 3 8
VTVT vTv Therapeutics MetabolicRespiratory Rare 3 Phase 3 8
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 5
XNCR Xencor HematologyImmunology+4 Rare 6 Approved 36
XERS Xeris Biopharma MetabolicNeurology Rare 1 Approved 4
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 2 NDA Submitted 11
ZURA Zura Bio DermatologyImmunology Rare 3 Phase 2 5